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Abstract
Chronic hepatitis C virus (HCV) infection, associated with severe liver disease and cancer, affects 70 million 
people worldwide.  New treatments with direct-acting-antivirals offer cure for about 95% of affected individuals; 
however, treatment costs may be prohibitive in both the poorest and richest nations. Opting for cure may require 
sacrificing essential household assets. We highlight the financial dilemmas involved, drawing parallels between 
Ethiopia and the United States, countries where universal health coverage does not yet exist. The World Health 
Organization (WHO) declaration for HCV eradication by 2030 will only become reality if universal access to 
efficacious and affordable treatment is guaranteed for everyone. 
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The patient lay in the bed in the crowded emergency room of the Gondar University Hospital, in northern Ethiopia, barely attentive to the crowd of doctors 
surrounding him during morning rounds. The residents 
presented the case to their attending physician. The patient 
was a 40-year-old male who presented with a gradual onset 
of fatigue, jaundice, loss of appetite and increased abdominal 
girth. On physical examination, he looked malnourished, with 
temporal wasting, icteric sclera, and abdominal swelling with 
shifting dullness. His blood test showed that he was positive 
for hepatitis C virus (HCV) antibody and he was diagnosed 
with hepatic decompensation and ascites due to cirrhosis, 
secondary to chronic HCV infection. A plan was agreed. The 
medical team would tap the ascites and offer nutritional and 
supportive care. 
The attending physician asked the house staff if they were 
aware of a new access program providing treatment for HCV 
at highly subsidized rates, offering potential to cure the 
disease. Did they suggest this to the patient? They replied 
that indeed they had mentioned it, but the patient could not 
afford the medication; he was a poor farmer. The attending 
physician asked “How many oxen does he have? If more than 
one, tell him to “sell an ox.”
Hepatitis C, affecting over 70 million people worldwide,1 has 
traditionally been considered a lifelong infection, associated 
with a high risk of cirrhosis, hepatocellular carcinoma, hepatic 
failure, serious extra-hepatic manifestations and premature 
death. Now, however, direct-acting antiviral (DAA) therapies 
promise elimination of the virus in almost 95% of cases.2 To 
this end, Target 3.4 of the Sustainable Development Goals aims 
to reduce mortality by one third from non-communicable 
diseases.3 As such global eradication of hepatitis C by 2030 is 
currently viewed as a realistic goal,4 5 but only if Target 3 of the 
Sustainable Development Goals, universal access to effective 
care can be guaranteed.
In an equitable world, all HCV-infected patients would 
have an equal chance to access treatment. One of the ironies 
of global health is the fact that many citizens of the richest 
and most citizens of the poorest countries in the world, are 
denied the chance of cure for HCV. In the case of the patient 
in Gondar, the ox is both a literal and figurative entity. The 
decision whether or not to sell an important asset, such as an 
ox, has relevance both literally and metaphorically far beyond 
the borders of Ethiopia.
The 2000 World Health Report noted that “Since the poor 
are condemned to live in their bodies just as the rich are, 
they need protection against health risks fully as much.”6 
According to this report, one of the objectives of a health care 
system is “providing financial protection against costs of ill-
health including the burden that a specific illness places on 
individuals and their families, but also the cost of care and 
cure.” Curative therapies may be associated with substantial 
charges for new drugs and technologies as well as ancillary 
costs. In the case of DAAs these include diagnostic testing, 
patient transportation to a care centre, imaging and end of 
therapy viral load testing to establish eradication or sustained 
viral response. DAAs may be genotype-specific, requiring 
genotypic confirmation of the HCV strain, or pan-genomic 
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(obviating the requirement for genotyping). 
Although current guidelines advocate therapy for all 
infected individuals, regardless of the extent of liver fibrosis,7 
some countries have restricted access to DAA to those with 
advanced disease (requiring imaging to confirm fibrosis) 
or to those who have quit or have promised to refrain from 
alcohol consumption. 
The price of cure for HCV varies widely across countries, 
with costs ranging from $300 to $84 000 per course – almost a 
3000% difference .8 This variability stems from many sources, 
including disparities in patent law, availability of generics, the 
vagaries of domestic and international pharmaceutical pricing 
etc. Thus, depending on where you live, affordability of DAAs 
fluctuates widely. In the African context, even expanded access 
programs incur costs equivalent or exceeding 100%-300% 
of the yearly income for the poorest populations.9 Recently, 
a highly subsidized program, supported by manufacturers, 
has been inaugurated in Ethiopia for expanded access for 
treatment of HCV with a genotype-specific DAA. 
A review of three months’ data from the laboratory 
in Gondar University Hospital found 90 blood samples 
positive for HCV antibody. Forty-five patients were found 
to be eligible for treatment and were counselled to receive 
treatment but only four had initiated DAA therapy, primarily 
because of significant financial barriers. Table outlines the 
costs involved, which can be considered representative for 
public hospitals in Ethiopia.
So why suggest the patient sell an ox? Eighty percent of 
Ethiopia’s 105 million inhabitants still live in rural areas and 
engage in farming. Oxen are used as draught animals and 
as sires of calves. But they also act traditionally as a type of 
insurance policy. Minimally a pastoral family requires at least 
one ox for survival, especially for ploughing and other field 
activities, but a second ox can be used as a hedge against 
personal calamity,10 This insurance may also be communal, 
since traditionally, when a member of village falls ill, or 
suffers another financial catastrophe, another villager(s) may 
sell an ox to underwrite the expenses of medical care for his 
neighbor. 
Prices of livestock vary according to the season,11 and 
according to conditions elsewhere in the country and, beyond 
it, in neighbouring countries. The farmer can, however, expect 
to realise a sum that is approximately equivalent to the annual 
gross domestic product (GDP) per capita in Ethiopia (Table).12 
This is a lot of money, much more than the approximately 
2% of GDP that people in low- and middle-income countries 
report being willing to pay annually for health insurance.13 
Patients such as the man in the hospital in Gondar have a 
choice. He can sell an ox to purchase treatment that will, very 
likely, save his life. Or he may decide that the cost is too high 
for him and his family and take a chance. The decision has 
nothing to do with clinical need. Rather, the most important 
factor may be whether he has one ox or two. And the farmer’s 
decision is far from irrational; if he has only one animal, 
selling it could very well lead to a downward spiral into debt, 
affecting him and his family, from which there is little chance 
of escape. He could also borrow money to finance his cure, 
but that again will put him in debt. According to the World 
Bank, approximately 9% of Ethiopians do borrow to pay for 
medical care; similarly 7% of rural Americans need to borrow 
to finance medical debt.14
So from Gondar, we move to the United States. Initially, 
HCV DAAs were priced at $60 000 to $80 000 for a 12-week 
course of treatment, although a newer agent glecaprevir/
pibrentasvir (Mavyret; AbbVie, North Chicago, IL) has a 
markedly lower price tag of $26 400 for an 8-week treatment.15 
Once again, as in Ethiopia, the decision to accept treatment 
in the United States is based not on clinical need but rather 
on the patient’s financial/insurance status. The share of 
the population lacking health insurance is much higher in 
Ethiopia than in the United States. The Ethiopian Community 
Based Health Insurance scheme covers only an estimated 11 
Table. Pharmaceutical and Ancillary Costs Involved in Receiving DAAs for HCV in Ethiopia
Item Price in ETBa US$ Equivalent £ Equivalent
Drug for 3 months 18 000 585.4 444.7
Drug for 6 months 36 000 1170.7 889.3
Non-pharmaceutical costs
HCV antibody test 50 1.6 1.2
Liver and renal function tests 300 9.8 7.4
Complete blood count 50 1.6 7.4
Ultrasound 200 6.5 4.9
Viral load (start of treatment) 1500 48.8 37.1
Viral load (end of treatment) 1500 48.8 37.1
Genotyping 5000 162.6 123.5
Transport 300 9.8 7.4
Total non-pharmaceutical costs 8900 289.4 219.9
Price of an ox 15 000-25 000 487.8-650.4 370.6-494.1
GDP per capita 2018 25 500 829.3 629.9
Abbreviations: HCV, hepatitis C virus; GDP, gross domestic product; DAAs, direct-acting antivirals.
a ETB: Ethiopian Birr, exchange rates 30.7 Birr/$, 40.5 Birr/£ as at December 5, 2019.
Note: Drug prices were obtained from the list of the Ethiopian Pharmaceutical Fund and Supply Agency, which purchases medicines for all public hospitals and 
supplies them at a subsidized cost. Costs of viral load and genotype testing are also consistent across the country as they are undertaken in India, arranged 
by an Ethiopian laboratory agent. Ultrasound, haematology, and clinical chemistry costs, which represent a small share of the total, are the reported national 
average for government hospitals and private clinics, although these costs can be higher in large cities such as Addis Ababa.
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million, or 10.5% of the population,16 while a nascent Social 
Health Insurance scheme covers a relative small number of 
workers in the formal sector, leaving about 85% of people 
without cover, while 27.5 million Americans, or 8.5% of the 
population lack insurance.17 However, those Americans who 
are uninsured, and many more whose coverage is limited, 
must cover this entire expense, as well as the ancillary costs of 
testing and transport, all out of pocket. 
Even if they are insured, American patients may struggle 
to obtain the requisite approval for DAA treatment, 18 and it 
is not unusual for insurance companies to demand a 20% to 
30% cost-sharing responsibility to be borne by the patient.19 
Cost sharing of up to $12 000 means that the cost of cure for 
HCV in the United States is roughly equivalent to the price 
not of an ox, but that of the cheapest car, or about 20% of the 
GDP per capita of the United States. Inevitably, this generates 
inequalities and, as with the sale of an ox, the loss of a car may 
similarly impair a family’s ability to obtain income, especially 
if they live in a rural area lacking public transport. 
Even among those insured by Medicare, out-of-pocket 
expenses for HCV treatment for those without low-income 
subsidies is estimated at $6297 to $10 889.20 Among those 
enrolled with Kaiser Permanente, one of the major health 
maintenance organisations, Hispanics, African Americans 
and other minorities are less likely to initiate therapy than 
whites, as are those with behavioral risk factors (such as drug, 
alcohol and tobacco misuse) as well as HIV co-infection.21
Yet, not surprisingly, when treatment is offered to the 
uninsured in financial assistance programs which cover both 
pharmaceutical costs and testing, compliance and treatment 
outcomes were found to be similar to those of insured 
patients.22 
For many Americans, costs of medications and illness can 
be major determinants of personal bankruptcy and home 
foreclosures.23 In a recent survey of a representative sample 
of the US population, when asked to “choose between 
two treatments, identical in every way except for their 
probability of a cure and their risk of driving the individual 
into bankruptcy,” the majority (70.5%) stated that they 
would choose cure “at all costs,” even at risk of bankruptcy, 
21% weighted cure and financial protection equally and a 
surprising 8.5% chose financial solvency over cure.24 Thus, 
the dilemma of selling an ox, or an ox-equivalent, is a 
common one in countries where universal health coverage is 
unavailable due to financial constraints, lack of political will, 
or both. Just like the man in Gondar, due to a lack of universal 
health care, many Americans with hepatitis C must make 
choices. They too face the risk of a downward spiral into debt.
In an ideal world, the promise of cure for HCV should 
become a reality for all its citizens. Governments, non-
governmental organisations and the pharmaceutical industry 
have shown that they can co-operate in the treatment and 
control of infectious diseases. Creative solutions need to be 
devised to adequately reward pharmaceutical companies 
for their advances.25 Furthermore, concerted efforts similar 
to those made in the face of HIV-AIDS need to be made to 
rid the world of HCV and to ensure access to curative care 
for patients whether they live in Africa or America; all this 
without their having to compromise their homes, their 
livestock, their livelihoods or their lives.
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